MPSQ1 FY27
MPS Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹2,697P/E: 27.1Market Cap: ₹5.0K CrSector: Printing & Publication
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Corporate Learning expects continued growth with multiple enterprise engagements near $1 million and a strong pipeline of new clients, aiming for organic growth around 12%.
- →Education segment grew 42.2% YoY, driven by strong AI-enabled content and new lanes like AI-generated content quality checks, with healthy pipeline and international expansion planned.
- →Research Solutions is growing steadily, with segment revenue up 13.2% YoY, focusing on AI-based knowledge solutions and integrity checks.
- →Unbound Medicine's recurring, high-renewal subscription model adds predictable revenue streams; expected to reach Rule of 40 (growth + EBITDA margin >40%) soon.
- →Overall company organic growth targeted in the late teens, outperforming market growth rates (Research ~15%, Education ~15%, Corporate Learning aims to catch up from current 6-7%).
- →FY’27 guidance is to comfortably cross INR 300 crore EBITDA with strong conviction, signaling confidence in growth and margin expansion.
Margin guidance
Category 3- →FY’27 guidance expects to comfortably cross INR 300 crores in EBITDA, viewed as a floor rather than a ceiling.
- →Three-year EBITDA CAGR projected at roughly 21% from FY’24 to FY’27.
- →FY’28 targets approximate INR 1,500 crores revenue and INR 450 crores EBITDA.
- →Q1 FY’27 is the strongest first quarter historically, with EBITDA margin expanding to 34.3%.
- →EPS for Q1 FY’27 at INR 29.70, up from INR 20.78 YoY.
- →Organic growth aspirations are higher than current early teens; aiming for late teens growth.
- →EBITDA margin improvements driven by AI-enabled and outcome-based revenue models.
- →Focus on operational leverage: revenue growth translating into margin expansion without significant headcount increases.
- →Unbound Medicine integration is expected to contribute to predictable and recurring revenue streams with improving margins.
- →Cash flow strong: INR 15-18 crores monthly, supporting acquisitions without equity dilution.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company prefers funding acquisitions through internal cash accruals and debt rather than equity.
- →Current cash accruals are about INR 15-18 crores per month (total around INR 138 crores).
- →Comfortable debt capacity is around INR 200 crores, allowing acquisition financing in the INR 300-500 crores range via cash plus debt.
- →Rahul Arora stated he does not foresee raising equity unless absolutely necessary but does not completely rule it out ("never say never").
- →The approach is to avoid equity raising due to its high cost to shareholders.
- →The company aims to balance cash flow and debt for acquisitions while maintaining financial discipline.
Order book
The provided transcript from MPS Limited's Q1 FY’27 Earnings Call does not explicitly mention the current or expected order book or details about pending orders. However, relevant insights include:
- The company has a healthy pipeline across its largest relationships, particularly in Education and Corporate Learning segments.
- The opening quarter reflected strong business momentum with revenue and EBITDA growth suggesting ongoing and expected demand.
- Emphasis is on expanding international knowledge organizations and growing existing accounts through cross-selling and AI platform enablement.
- MPS focuses on outcome-based revenue models that contribute to recurring and deferred revenue streams.
- The company aims for steady organic growth and selective acquisitions to build strategic assets, reflecting confidence in sustained order flow.
- The work to deliver FY’27 targets is already in flight, indicating a robust backlog supporting guidance.
No specific numerical order book or order backlog figures are disclosed in the call.
Capex plans
Yes- →No explicit mention of current or planned capital expenditure (capex) in the provided transcript.
- →Focus appears to be on organic growth, AI integration, and strategic acquisitions rather than heavy capital investments.
- →Strategic investments focus on AI-enabled solutions, acquisitions of assets with existing strength, and expanding recurring revenue streams (e.g., Unbound Medicine).
- →Acquisition strategy targets companies with revenue above $15 million, mainly in education, science domains where AI acts as a multiplier.
- →Financing for acquisitions expected through internal cash accruals and debt (INR 300-500 crores range); minimal reliance on equity raising.
- →Continuous R&D investment in MPS Labs for AI and engineering indicated, supporting product and process innovation.
- →Overall, emphasis on leveraging AI for operating leverage and margin expansion rather than traditional large-scale capex.
How does MPS rank vs peers in Printing & Publication?
Pro feature1MPS
Rev 3Mar 3
See full Printing & Publication sector rankings
How does MPS rank in Printing & Publication?
Compare MPS against every Printing & Publication company (Q1 FY27) on revenue, margins and earnings-call signals.